SLS Stock In The Spotlight As CEO Pushes Back On Regal Trial Criticism – ‘Let’s Separate The Noise From The Data’
CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.
Read the full articleYou might also wanna read
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
SpaceX skeptics have added reason for concern after Musk comments diverge from IPO filing
#SpaceX skeptics have added reason for concern after #ElonMusk comments diverge from #IPO filing buff.ly/3nRNZAA #tech #space #investing #Fi
Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could a
AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure
AstraZeneca stock fell 9% after its Wainua heart drug trial missed its primary goal, raising questions about management credibility.
On the Move: Aura Names Young CMO
Aura , an AI-powered online safety solution, names Steven Young as global CMO. Young was most recently CMO at social commerce platform Poshm
Ex-Xbox dev slams game execs as ‘money grubbing idiots’ in quote of the year
The recent spate of Xbox layoffs has prompted a former employee to share an anecdote about how one exec suggested turning Halo into Diablo.
Comments
Sign in to join the conversation.
No comments yet. Be the first.